COLUMBUS, Ohio--(BUSINESS WIRE)--Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton’s antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer. In the study, Enlyton’s targeting agent increasingly localized in tumor, while 18F-FDG did not. 18F-FDG also exhibited the tendency to localize in normal tissues. Dr. Edward Martin Jr. (Enlyton CSO and Professor of Surgery at The Ohio State University) said, “We are excited with the results of the study and the potential it offers for successful use of our cancer-specific targeting agent in clinical trials for preoperative, intraoperative, and postoperative PET-based imaging of colorectal cancer.”
